

# ASCO Direct™ GU Highlights Meeting

## Update in Genitourinary Cancers



### Program, Saturday, February 27, 2021

- 09:00 - 09:10**      **Welcome & Start of the program - Jörg Beyer**
- 09:10 - 10:30**      **Prostate Cancer - Chair: Thomas Hermanns, Thomas Zilli**
- 09:10 - 09:25**      **Aurelius Omlin**  
Hot topics in prostate cancer
- 09:25 - 09:40**      **Anuradha Gopalan**  
Redefining high-risk prostate cancer: beyond clinical parameters
- 09:40 - 09:55**      **Ida Sonni**  
Head-to-head comparison of 68Ga-PSMA-11 PET/CT and mpMRI in the detection, intra-prostatic localization, and local extension of primary prostate cancer: A single-center imaging study with histopathology gold standard
- 09:55 - 10:10**      **Pirus Ghadjjar**  
Dose-intensified versus conventional dose-salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: Six-year outcomes of the SAKK 09/10 randomized phase III trial
- 10:10 - 10:25**      **Mike Sathekge**  
Lighting the Way: Lutetium in the Treatment Paradigm
- 10:30 - 10:45**      **Break**
- 10:45 - 11:45**      **Penile Cancer - Chair: Aurelius Omlin, Thomas Zilli**
- 10:45 - 11:00**      **Thomas Hermanns**  
Overview of treatment options and controversies in penile cancer
- 11:00 - 11:15**      **Curtis Alvin Pettaway**  
Surgical Management of Inguinal and Pelvic Nodes in the Treatment of Penile Cancer
- 11:15 - 11:30**      **Lance C. Pagliaro**  
Role of Perioperative Chemotherapy in the Treatment of Penile Cancer
- 11:30 - 11:45**      **Anthony L. Zietman**  
Role of Chemoradiation in the Treatment of Penile Cancer: Neoadjuvant, Definitive, and Postoperative
- 11:45 - 12:00**      **Break**
- 12:00 - 12:30**      **Keynote Lecture      Chair: Wolfram Jochum**
- William G. Kaelin**  
The von Hippel-Lindau Tumor Suppressor Protein: Rosetta Stone for Kidney Cancer Pathogenesis and Treatment
- 12:40 - 13:30**      **Lunch Break**

<b>13:30 - 15:00</b>	<b>Kidney Cancer - Chair: Jörg Beyer, Thomas Hermanns</b>
<b>13:30 - 13:45</b>	<b>Dominik Berthold</b> Renal cell cancer: what are the relevant issues in 2021
<b>13:45 - 14:00</b>	<b>Robert J. Motzer</b> Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study)
<b>14:00 - 14:15</b>	<b>Chun Loo Gan</b> Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)
<b>14:15 - 14:30</b>	<b>Sumanta K. Pal</b> Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study
<b>14:30 - 14:45</b>	<b>David Braun</b> Breathing new life into clear cell therapies with HIF2 therapies
<b>14:45 - 15:00</b>	<b>Shankar Siva</b> Stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumors: The RAPPORT trial
<b>15:00 - 15:15</b>	<b>Break</b>
<b>15:15 - 16:00</b>	<b>Testis Cancer- Chair: Aurelius Omlin, Thomas Hermanns</b>
<b>15:15 - 15:30</b>	<b>Jörg Beyer</b> Fine tuning at its best. Improving prognosis in testis cancer
<b>15:30 - 15:45</b>	<b>Jonathan K. Joffe</b> Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: Results from a randomized, phase III, factorial trial (TRISST)
<b>15:45 - 16:00</b>	<b>Siamak Daneshmand</b> SEMS trial: Result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma
<b>16:00 - 16:15</b>	<b>Break</b>
<b>16:15 - 17:20</b>	<b>Bladder Cancer - Chair: Dominik Berthold, Thomas Zilli</b>
<b>16:15 - 16:30</b>	<b>Thomas Hermanns</b> Bladder cancer: what are the relevant issues in 2020
<b>16:30 - 16:45</b>	<b>Dean F. Bajorin</b> First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC)
<b>16:45 - 16:55</b>	<b>Tracy L. Rose</b> Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC)
<b>16:55 - 17:05</b>	<b>Monika Joshi</b> Phase II clinical study of concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: Results for primary analyses and survival
<b>17:05 - 17:20</b>	<b>Thomas Powles</b> Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma
<b>17:20</b>	<b>Closing Remarks</b>
<b>17:30</b>	<b>End of program</b>